Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Well, ANTH was down by -0.0040 or -1.71% to 0.23 today with the Same bottom 0.225 as yesterday but a-tick-higher top 0.24! 0.24 is still a very strong resistance! I bet the insiders are diluting large amount of free shares everyday. Otherwise why 0.24 is a top ceiling?
However ANTH has already formed total Six bottom supports at $0.213, $0.2131, $0.2142, $0.216, $0.2212, and $0.225. Hopefully the coming Nasdaq-Delisting process won't crash the price down to $0.1025 by dropping -53.052% thought its NYSE-Delisting peer (RASF) had already crash its price down by -48.125% (from NYSE to OTCQB) just a couple of weeks ago!
Anyway in the worst case ANTH should hold the New bottom at $0.1 in the coming days/weeks. I've already sold over 200K shares at 0.23 ~ 0.24 for small gain. Now I'm still holding over 900K shares and wait for 0.24 ~ 0.31 to make huge Quick profit once 0.24 is broken out!
A breakou seems to be called for by the chart. I expect to see a pop starting tomorrow. Could see a retrace up from here. Chart bottomed out. Time for a BIG bounce.
IMO, the company Liquidation or Dissolution should give more value to our common shares since the so-called acquisition or merger transaction usually means Huge amount of ownership Dilutions to the existing ANTH shareholders! I bet the liquidation value is around $0.1 ~ $0.12 a share v.s. the merger value is below $0.1 a share!
The winding down process might cost Millions of dollars while the Quick Liquidation could cut this kind of cost significantly!
However Nasdaq-Delisting process might cause 50% price crash if ANTH replicates the outcome of its NYSE-Delisting peer RAS (now RASF) did a couple of weeks ago! So the worst case will push ANTH down to as low as $0.1 in the coming days or weeks... Which is why I reserve a lots of cash for the further average-down thought I still hold near 1M shares!
Anyway it is very nice to see ANTH bounce to $0.2399 again today from Monday's $0.216 ($0.213 is the current Bottom)! I'm lowering my selling target to $0.23 ~ $0.31 in case $0.24 is the ceiling price before another price crash...
Value_Investor, that's a very good question. I'm going to average down myself and hope that there is some type of recovery. But it's not looking good seeing that they no longer have valid contact information.
It also doesn't help that on 5/23/2018 Anthera warned that without a transaction it could dissolve or liquidate followed closely the same day with "Anthera has disclosed that it has began winding down activities in April". DJCNews
I'm out on the spike earlier. On watch for now!
GL
What happened with ANTH? The company phone number (510) 856-5600 is now disconnected and there is no any Transfer Agency for ANTH at all!
Will the stock be downgraded to the OTC Pink Sheet market as soon as tomorrow since it has already passed Nine business days while they said (on May 23) ANTH will be De-listed from Nasdaq Seven days later if no action from the company?
https://ih.advfn.com/p.php?pid=nmona&article=77505620
Anyway I might lower my selling price to $0.23 ~ $0.32, instead of $0.25 ~ $0.35! I would cut partial positions at $0.23 ~ $0.24 for small gains first, then use all the proceeds to buy back ANTH at $0.15 ~ $0.213 since ANTH is heading down to $0.1xxx...
I bet the company is still diluting huge amount of shares to the market everyday which is why ANTH has stuck at $0.213 ~ $0.24 for so long!
Who were selling the "endless" shares at $0.213 ~ $0.24? Why ANTH has not bounced to $0.25 or higher yet after Seven Consecutive Business Days long heavy sell-off? If ANTH couldn't break up the strong resistance $0.24 then the coming stock de-listing news will push it down to $0.1xxx as soon as tomorrow...
Why the new Bottom is $0.15?
I have no any confidence with the existing crap CEO! What he did is just damage all the shareholder's equity and value by the Endless Huge dilutions (last quarter alone he diluted 3M shares) and Repeated Big R/S plus very greedy salary+bonus+stock-option for himself by doing nothing good to either the company or shareholders!
However I do have confidence with the stock's own valuation at the current oversold and undervalued price levels which is why I invested hundreds of thousands of dollars to own over 1M shares!
When ANTH is downgraded to the OTC Pink Sheet market (from Nasdaq exchange) next week we might see the new low $0.1xx then. Now I'm preparing up to $300K cash to buy more shares at $0.1xx. Anyway I would flip once first should ANTH start the strong bounce from the current bottom $0.213! Hopefully no more Big R/S risk due to the CEO's dissolution/liquidation and downgrading plan...
My selling price area is $0.25 ~ $0.35 since I bet no way to go above $0.35 due to what the crap CEO did.
Yes, because the majority of my ANTH shares were bought at $0.213x ~ $0.22xx. Even selling at $0.25 my position will have 14% nice gain!
If ANTH breaks down $0.213 and crash to $0.1xx then I'll buy more shares to average-down my cost base. I bet there is no way to break down $0.1 based on its final liquidation valuation thought the stock might be downgraded to the OTC Pink Sheet market as soon as next week!
1M cheap shares? cool!
GLTY
It seems $0.213 is the current Bottom though the shorters and naked shorted may try to break it down again! What is the reason for ANTH to crash to Pennies (i.e. $0.0xxx)? True, there is nothing in the pipelines. But ANTH still has Millions of Dollars cash at hand which should entitle each common share at least $0.1 per share liquidation valuation! The coming De-listing will kick in within just a week per the company filing which might push the price down again. However $0.1xxx will be the Final Bottom!
Anyway I'll continue to average down till $0.1xxx! Glad to own over 1M cheap shares now! I'll sell ANTH at $0.25 ~ $0.35 to make huge gain very soon...
No more Big R/S risk here! No more Endless Huge dilutions risk here!
Another New low $0.213 so far! What is the reason for ANTH to crash further to $0.1? I just added more shares.
Will the company file the CH11 bankruptcy? IMO, the worst case will be the stock De-listing from Nasdaq and company Liquidation which should kick in very soon...
My confidence is still high considering Dr. Christopher Henney as the Chairman of BOD. Pretty sure he led the recent acquisition of Cascadian Therapeutics (formerly Oncothyreon)of which also the chairman of bod, by Seattle Genetics. He is also a director at Cyclacel Pharmaceuticals (CYCC).
GL
Why do you think this current sp is too low? They just got de-listed and have nothing in the pipeline...seems like pennies coming?
Those very sick manipulators just crash ANTH to another new low $0.2196! Now I hold over 1M shares and shall sell them at $0.267 ~ $0.367 for huge gain very soon! If any silly MM breaks down the current Bottom then I'll add many many more dirt cheap shares...
Delisting, so going down to about 10 cents.
Value_Investor, I've been buying each day on the lows and I'll be doing the same.
New low $0.2301? What happened today? Bankruptcy Liquidation? Nasdaq De-listing to OTC Pink Sheet market? Why has ANTH crashed 23.33% from the previous Bottom $0.3001? It seems some serious manipulations here since ANTH broke down $0.3001! Anyway I bought and hold near 1M dirt cheap shares now and I'll sell those shares at $0.277 ~ $0.367 later to make huge profit very soon!
Uh oh....
Item 3.01. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.
On May 22, 2018, Anthera Pharmaceuticals, Inc. (the “Company”) received a letter from The Nasdaq Stock Market (“Nasdaq”) informing the Company that its most recent Form 10-Q for the period ended March 31, 2018 disclosed that the Company has suspended further clinical development of Sollpura and began to wind down activities including suspending further development of its only other licensed drug compound, blisibimod. The Company is exploring strategic transactions and noted that if a strategic transaction is not consummated, the Company may be required to dissolved or liquidate. In that regard, any strategic transaction that involves a merger or acquisition would likely be a business combination that results in “Change of Control” pursuant to Listing Rule 5110(a), which would require the post-transaction entity to satisfy all of Nasdaq’s initial listing criteria and to complete Nasdaq’s initial listing process. Furthermore, the bid price of the Company’s listed common stock was not in compliance with the continued listing requirements due to the bid price closing at less than $1.00 for more than 30 consecutive business days, and as a result, does not comply with Listing Rule 5550(a)(2).
The letter stated that the Company may appeal the Staff’s determination to a Hearings Panel (the “Panel”) within seven days from the receipt of the letter. A hearing request will stay the suspension of the Company’s securities pending the Panel’s decision. The Company intends appeal the Staff’s determination.
Anthera Pharmaceuticals Inc $ANTH Expected to Announce Earnings of -$0.60 Per Share
https://www.americanbankingnews.com/2018/05/22/anthera-pharmaceuticals-inc-anth-expected-to-announce-earnings-of-0-60-per-share.html/amp
Our day will come, believe...
We need a blockbuster news to go uptrend! Enough of this eroding pps.
FY2020 REVENUE EVALUATION FOR ANTHERA PHARMACEUTICALS INC. (ANTH) ISSUED BY SUNTRUST BANKS
http://bangaloreweekly.com/2018-05-20-fy2020-earnings-estimate-for-anthera-pharmaceuticals-inc-anth-issued-by-suntrust-banks/
Is Selling Anthera Pharmaceuticals, Inc. (ANTH) Here a Winning Strategy?
https://friscofastball.com/is-selling-anthera-pharmaceuticals-inc-anth-here-a-winning-strategy-2/
Anthera Pharmaceuticals (ANTH) Expected to Announce Earnings of -$0.60 Per Share
https://www.thelincolnianonline.com/2018/05/15/anthera-pharmaceuticals-anth-expected-to-announce-earnings-of-0-60-per-share.html
Stock in Buy Zone: Anthera Pharmaceuticals, Inc. (ANTH)
https://www.streetobserver.com/2018/05/15/stock-in-buy-zone-anthera-pharmaceuticals-inc-anth/
If ANTH could hit $5.25 (Average Target Price from Brokerages) in 2018 then over One Hundred New Millionaires will be created from investing this hidden gem...
Open road for return $2
Today the greatest news for ANTH is, the Book Value was increased to Positive $0.21 a share from last quarter's Negative -$0.42 a share based on today's Good 10-Q report! That is $0.63 per share Huge BV increasing!
Also the Cash Value was increased to Positive $0.31 a share from last quarter's Positive $0.09 a share! That is $0.22 per share Huge CV increasing!
Today's 10-Q report shows Very Positive progresses on both BV and CV! ANTH now has much much stronger financial balance sheet!
Easy double from current Basement price levels based on its current Hyper Undervalued and Hyper Oversold status! There is an huge Gap between $0.57 and near $3!
ANTH worth $0.6 a share at least in any Buy-Out or Reverse-Merger deal...
Quarterly Report (10-q)
https://ih.advfn.com/p.php?pid=nmona&article=77436542
4 Bullish Analysts Covering Anthera Pharmaceuticals, Inc. (ANTH)
https://www.mmahotstuff.com/2018/05/14/schnieders-capital-management-has-boosted-by-335500-its-bristol-myers-squibb-co-bmy-stake-4-bullish-analysts-covering-anthera-pharmaceuticals-inc-anth.html
Anthera Pharmaceuticals (ANTH) Receives $5.25 Average Target Price from Brokerages
https://www.dispatchtribunal.com/2018/05/14/anthera-pharmaceuticals-anth-receives-5-25-average-target-price-from-brokerages.html
The most recent high was $0.57 --- see the chart below! ANTH is Hyper Oversold since around $3 and Hyper Undervalued now! Easy double from the current bottom to hit $0.6 again! $0.68 Cash Value!
The first real bounce for this hidden gem will hit $0.4277!
Anyone who sold their shares below $0.35 will soon kick themselves!
Accounting & Governance Risk Overview: Anthera Pharmaceuticals Inc.
BY Audit Integrity Research
— 3:34 PM ET 05/09/2018
Anthera Pharmaceuticals Inc (ANTH) is currently rated as having Very Aggressive Accounting & Governance Risk (AGR®), receiving an AGR score that places them in the 2nd percentile among all companies in North America rated by GMI, indicating higher accounting and governance risk than 98% of the other companies.
I hope you're right! My other holding mymx as well.
Yes, ANTH was raised to $0.358 in the AH session of yesterday! Hyper Oversold since near $3! Extremely Undervalued based on the current market value against its real valuation and large amount of cash...
This stock will go minimum. 100% profit. Be patient.
This hidden gem will explode in the coming week! Easy 100% bounce!
If/when the earnings for ANTH comes out on May 8th and they're decent, there should definitely be a move upward, IMO of course. I'm hoping for good news and a even better run north.
Followers
|
57
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
2495
|
Created
|
03/01/10
|
Type
|
Free
|
Moderators |
Anthera Pharmaceuticals Inc.
Nasdaq: ANTH
Contact Info
25801 Industrial Blvd, Suite B • Hayward, CA 94545
Press Contact: pr@anthera.com
Business Development: bd@anthera.com
Vendors: ap@anthera.com
Website: www.anthera.com
J. Craig Thompson promoted to Chief Executive Officer and appointed to the Board of Directors Paul F. Truex appointed as Executive Chairman of the Board Dr. Christopher Henney stepped down as Chairman ...
http://finance.yahoo.com/q?s=ANTH
Anthera Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing products to treat serious diseases associated with inflammation,
including cardiovascular and autoimmune diseases. We currently have a Phase 2 clinical program, blisibimod.It was just recently approved by FDA to move into
PHASE 3
Blisibimod targets elevated levels of B-cell activating factor (BAFF), which has been associated with a variety of B-cell mediated autoimmune diseases, including systemic lupus erythematosus (SLE), rheumatoid arthritis, multiple sclerosis, Sjögren's Syndrome, Graves' Disease and others.
It has taken the lupus research community over 50 years to produce a new therapy. Although it is now a year old, Benlysta (belimumab),
now marketed by GlaxoSmithKline and Human Genome Sciences, is the first human monoclonal antibody for the treatment
of lupus.
Benlysta had a slow take-off grossing $59.2 million in sales in the last three quarters of 2011, but it was approved in numerous
countries by year's end. Estimated sales for Benlysta in 2012 are said to be about $230 million, with first annual profits likely by 2015.
The surprisingly slow uptake of Benlysta allows for blisibimod to develop into a promising drug as
it currently has more desirable features than that of Benlysta.
Blisibimod has a dosing regimen of one injection weekly, compared to that of Benlysta which requires a
series of dosing before the maintenance dose begins. Also, Benlysta has limitations on usage pertaining to
specific patient populations and has not been studied in combination with other biologics.
These attributes of blisibimod including a different mechanism of action, will set it apart from
Benlysta, Global Data concludes.
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |